INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 11, Issue 10- 2024

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.10.003

The Role of the Mentzer Index in Diagnosing Anemia During Pregnancy: A Review

*[1]Emmanuel Ifeanyi Obeagu and [2]Getrude Uzoma Obeagu
[1]Department of Biomedical and Laboratory Science, Africa University, Zimbabwe
[2]School of Nursing Science, Kampala International University, Uganda
*Corresponding Author: emmanuelobeagu@yahoo.com

Abstract

Anemia during pregnancy is a critical global health issue, often stemming from iron deficiency anemia (IDA) and thalassemia trait, both of which carry significant maternal and fetal health risks if misdiagnosed or left untreated. The Mentzer Index, calculated by dividing the mean corpuscular volume (MCV) by the red blood cell (RBC) count, serves as a practical and accessible tool for differentiating between these two types of microcytic anemia. With values above 13 typically indicative of IDA and values below 13 suggestive of thalassemia trait, the Mentzer Index offers a rapid, non-invasive screening option particularly valuable in resource-limited settings where access to advanced diagnostic methods is limited. The Mentzer Index's utility lies in its simplicity and minimal resource requirements, making it feasible for use in primary healthcare facilities. Understanding the pathophysiology behind IDA and thalassemia trait further supports its diagnostic role, as IDA often presents with reduced RBC counts, while thalassemia trait features high RBC counts despite small cell sizes. This distinction allows clinicians to tailor management strategies appropriately, such as prescribing iron supplements for IDA and avoiding unnecessary supplementation in thalassemia trait, which could lead to adverse outcomes due to iron overload.

Keywords: Mentzer Index, anemia in pregnancy, iron deficiency anemia, thalassemia, prenatal screening, maternal health

Introduction

Anemia during pregnancy is a significant global health concern, with an estimated 40% of pregnant women affected, primarily in low- and middle-income countries. This condition, marked by a reduction in hemoglobin levels below the

normal range, poses risks for both maternal and fetal health, including increased rates of preterm birth, low birth weight, and higher maternal morbidity and mortality.[1-3] The two most common types of anemia in pregnancy are iron deficiency anemia (IDA) and thalassemia, a genetic hemoglobin disorder. Differentiating between these types is essential, as they require distinct approaches for effective management. In this context, the Mentzer Index has gained attention as a cost-effective, non-invasive tool for initial anemia screening. Anemia in pregnancy occurs due to a variety of factors, including increased iron requirements, dietary deficiencies, and underlying genetic conditions such as thalassemia. IDA is the predominant form of anemia in pregnancy, often linked to nutritional deficiencies and heightened iron demands. In contrast, thalassemia traits, especially beta-thalassemia, contribute to anemia due to impaired hemoglobin synthesis. The symptoms and presentations of both IDA and thalassemia trait can overlap, making it challenging for clinicians to accurately diagnose without extensive testing. Misdiagnosis or delayed diagnosis can lead to inappropriate treatments, such as unnecessary iron supplementation, which can be harmful to women with thalassemia.[4-6]

The Mentzer Index, developed by William Mentzer in 1973, offers a straightforward means to distinguish between IDA and thalassemia trait.[7] This index is calculated using the mean corpuscular volume (MCV) divided by the red blood cell (RBC) count, resulting in a numerical value that aids in the differential diagnosis. Values greater than 13 generally suggest IDA, while values below 13 indicate a likelihood of thalassemia trait. Its simplicity and minimal resource requirements have made the Mentzer Index a valuable tool, especially in regions with limited access to advanced diagnostic methods, allowing for quick initial assessments. Early differentiation of anemia types enables targeted management, as IDA requires iron supplementation, while thalassemia trait management focuses more on monitoring and genetic counseling. For pregnant women with thalassemia trait, excess iron can accumulate, potentially leading to complications. Therefore, implementing the Mentzer Index as a first-line screening tool can prevent inappropriate treatment and improve outcomes for both the mother and fetus. While effective, the Mentzer Index is not without limitations. It provides an initial estimation and should ideally be complemented by further diagnostic tests, particularly in ambiguous cases where values are borderlines. Additionally, coexisting conditions, such as combined iron deficiency and thalassemia, can reduce the accuracy of the Mentzer Index. To address these challenges, clinicians can use additional hematological indices, such as red cell distribution width (RDW) and Shine and Lal Index, in conjunction with the Mentzer Index for a more comprehensive assessment. This review examines the role of the Mentzer Index in diagnosing anemia during pregnancy, assessing its efficacy, clinical utility, and limitations.

Overview of the Mentzer Index

The Mentzer Index is a diagnostic calculation used to help distinguish between two common causes of microcytic anemia: iron deficiency anemia (IDA) and thalassemia trait. First introduced by William Mentzer in 1973, this index is derived by dividing the mean corpuscular volume (MCV) by the red blood cell (RBC) count.[8] The resulting value provides a rough differentiation between IDA and thalassemia trait. A Mentzer Index greater than 13 generally indicates IDA, where the red blood cell count is often lower, while a value below 13 is more suggestive of thalassemia trait, characterized by a relatively high RBC count in the presence of microcytic anemia. This simple calculation can be especially helpful in settings where advanced diagnostic tools, such as hemoglobin electrophoresis or serum ferritin measurements, are not readily available. The underlying principle of the Mentzer Index is based on the different pathophysiological mechanisms of IDA and thalassemia.[9] In IDA, there is a shortage of iron available for hemoglobin synthesis, which leads to fewer and smaller red blood cells, decreasing the RBC count and raising the Mentzer Index

value. Conversely, in thalassemia, the genetic abnormality affects hemoglobin production but not necessarily RBC production, resulting in a higher RBC count despite smaller-than-normal red cells, hence lowering the Mentzer Index. The Mentzer Index is popular for its simplicity, cost-effectiveness, and ease of application, particularly in low-resource settings or primary healthcare facilities. It requires only basic hematological parameters (MCV and RBC count), making it a practical option for initial screening when more specific testing may not be feasible. For pregnant women, especially those in areas with high rates of both iron deficiency and thalassemia trait, the Mentzer Index provides a quick and accessible method for anemia assessment, guiding more specific management and intervention.

Despite its utility, the Mentzer Index is not a definitive diagnostic tool. It serves as a preliminary screening method and is less accurate in cases where anemia may be due to mixed causes, such as concurrent IDA and thalassemia, or other types of microcytic anemias. In such cases, additional indices like the red cell distribution width (RDW), Green and King Index, or serum ferritin levels may be needed to clarify the diagnosis. Furthermore, the Mentzer Index may produce borderline values, particularly around 13, which necessitates further testing for reliable classification.[8] In clinical practice, the Mentzer Index has shown good sensitivity and specificity in differentiating IDA from thalassemia trait, especially when used alongside other hematological indices. For instance, RDW is usually elevated in IDA but remains relatively normal in thalassemia. Integrating these indices allows clinicians to form a more comprehensive picture of the anemia's underlying cause and to make better-informed decisions regarding further testing or management.

Types of Anemia in Pregnancy

1. Iron Deficiency Anemia (IDA)

IDA is the most prevalent form of anemia in pregnancy, caused by insufficient iron needed for hemoglobin synthesis. Pregnant women require more iron to support increased blood volume, fetal growth, and placenta development, often making dietary iron intake inadequate. IDA is characterized by symptoms such as fatigue, weakness, pallor, and, in severe cases, shortness of breath and palpitations. Diagnosis is typically confirmed through serum ferritin levels and other iron indices, and treatment generally includes iron supplementation and dietary modifications to increase iron intake.[1]

2. Folate Deficiency Anemia

Folate, a B vitamin, is essential for cell division and fetal neural development, and its deficiency is linked to megaloblastic anemia. Pregnant women have higher folate requirements, and deficiency can lead to abnormal red blood cell formation, characterized by large, immature RBCs. Folate deficiency anemia may result in fatigue, weakness, irritability, and in severe cases, an increased risk of neural tube defects in the fetus. Supplementation of folic acid before conception and during pregnancy is a standard preventive measure.

3. Vitamin B12 Deficiency Anemia

This type of anemia, though less common, can occur in pregnant women, especially those with dietary restrictions (e.g., vegans) or absorption issues (e.g., pernicious anemia). Vitamin B12 is crucial for red blood cell formation and neurological health. Deficiency leads to megaloblastic anemia with symptoms similar to folate deficiency, including fatigue, weakness, and potential neurological issues like numbness or tingling. B12 supplementation is recommended for at-risk populations and is often given in combination with folic acid.

4. Anemia of Chronic Disease (ACD)

ACD, or anemia of inflammation, may develop in pregnant women with chronic conditions like infections or autoimmune diseases. In ACD, the body's inflammatory response disrupts iron

metabolism, leading to reduced iron availability despite normal or increased iron stores. ACD is generally normocytic (normal-sized RBCs) but can sometimes present as microcytic anemia. Managing the underlying condition, rather than iron supplementation alone, is often required to address this anemia type effectively.

5. Sickle Cell Anemia

Sickle cell anemia is a genetic hemoglobin disorder that leads to the production of abnormal hemoglobin, causing red blood cells to assume a rigid, sickle shape. These sickle cells are prone to premature destruction and can block blood flow, leading to painful crises, organ damage, and complications for both mother and fetus. Pregnancy in women with sickle cell anemia requires close monitoring due to higher risks of complications, including preterm labor and low birth weight. Treatment focuses on managing symptoms and preventing sickle cell crises.

6. Thalassemia

Thalassemia is a hereditary blood disorder that affects hemoglobin production, leading to microcytic anemia. The condition ranges from mild (thalassemia trait) to severe forms, such as beta-thalassemia major, which requires regular blood transfusions. In pregnancy, thalassemia can complicate anemia diagnosis, as the presentation overlaps with iron deficiency anemia.[10] Differentiating thalassemia from IDA is crucial, as iron supplementation in thalassemia patients can lead to iron overload. Diagnosis often involves genetic screening and the use of indices like the Mentzer Index.

7. Hemolytic Anemia

Hemolytic anemia occurs when red blood cells are destroyed faster than they are produced. This can be due to inherited conditions (e.g., hereditary spherocytosis) or acquired factors, such as autoimmune disorders. In pregnancy, hemolytic anemia can lead to fatigue, jaundice, and an increased risk of complications for both mother and fetus. Management involves addressing the underlying cause and may require blood transfusions in severe cases.[11-12]

Mentzer Index in Differentiating Anemia Types

The Mentzer Index is a simple, widely used hematologic calculation that helps differentiate between iron deficiency anemia (IDA) and thalassemia trait, two common causes of microcytic anemia, especially in populations with a high prevalence of both conditions. The index is calculated by dividing the mean corpuscular volume (MCV) by the red blood cell (RBC) count.[13] This formula yields a numerical value that serves as a preliminary indicator for distinguishing between IDA and thalassemia trait. In clinical practice, a Mentzer Index greater than 13 suggests IDA, while values below 13 typically indicate thalassemia trait. This cutoff is based on the typical presentation of these anemia types, where IDA generally features a low RBC count due to insufficient iron availability for red blood cell production, whereas thalassemia trait often presents with a higher RBC count despite the cells being microcytic. The principle behind the Mentzer Index lies in the different physiological mechanisms that lead to microcytic anemia in each condition. In IDA, the body lacks sufficient iron to produce adequate hemoglobin, resulting in fewer red blood cells and a smaller cell size (microcytosis). This reduction in RBC count raises the Mentzer Index value. In thalassemia trait, on the other hand, a genetic mutation affects hemoglobin synthesis but does not impact RBC production as significantly, resulting in a higher RBC count even though the cells remain small. This inverse relationship between RBC count and MCV is central to the utility of the Mentzer Index in initial anemia assessments.

While the Mentzer Index is helpful for preliminary screening, it is not definitive and should be interpreted with caution. It has some limitations, particularly when other forms of anemia or coexisting conditions, such as combined IDA and thalassemia, are present. For more accurate differentiation, the Mentzer Index

can be complemented with other hematologic indices, such as red cell distribution width (RDW) and the Shine and Lal Index. Integrating these additional indices helps improve diagnostic accuracy and provides a more comprehensive view, allowing clinicians to form better-informed decisions regarding further testing and management.[13]

Benefits of Using Mentzer Index in Pregnancy

1. Efficient and Low-Cost Screening Tool

The Mentzer Index is a quick and cost-effective method for differentiating between iron deficiency anemia (IDA) and thalassemia trait, two common causes of anemia in pregnancy. Calculated simply by dividing the mean corpuscular volume (MCV) by the red blood cell (RBC) count, it requires only basic hematological data, which are typically part of routine prenatal blood tests. This efficiency makes the Mentzer Index a practical tool, particularly in low-resource settings where advanced diagnostic tests may not be available.

2. Reduced Need for Invasive Testing

By helping to distinguish between IDA and thalassemia trait, the Mentzer Index reduces the need for more invasive and costly diagnostic procedures like genetic testing or hemoglobin electrophoresis. For pregnant women, avoiding unnecessary tests is crucial, as they may lead to increased healthcare visits, stress, and, in some cases, exposure to risks. Using the Mentzer Index can streamline the diagnostic process, allowing clinicians to make more targeted recommendations for further testing only when necessary.

3. Enhanced Maternal and Fetal Health Management

Differentiating between IDA and thalassemia trait is essential for appropriate treatment. In cases of IDA, iron supplementation is typically recommended to meet the increased iron requirements of pregnancy. However, in thalassemia trait, unnecessary iron supplementation can lead to iron overload and complications. The Mentzer Index provides a preliminary guide, allowing healthcare providers to better tailor anemia management strategies, which helps reduce risks like preterm birth, low birth weight, and complications associated with untreated anemia or inappropriate iron supplementation.

4. Facilitates Early Intervention and Prevention

Detecting anemia types early in pregnancy through the Mentzer Index enables timely intervention, potentially preventing adverse outcomes. Pregnant women with IDA who are identified early can begin iron supplementation promptly, helping to alleviate anemia symptoms and support fetal development. Those identified with thalassemia trait can avoid unnecessary interventions and instead focus on regular monitoring. Early intervention reduces the likelihood of severe anemia later in pregnancy, which can have significant health benefits for both mother and child.

5. Practicality in Primary Care and Resource-Limited Settings

The Mentzer Index's reliance on basic hematology parameters makes it especially useful in primary care and low-resource settings, where more specialized diagnostic equipment may be limited. Primary healthcare providers can use this index as a preliminary tool, which enhances accessibility to initial screening and helps direct limited resources toward those who require further testing or intervention. This practicality supports broader access to maternal healthcare and early anemia management, improving maternal and fetal health outcomes.

6. Promotes Tailored Nutritional Counseling

Using the Mentzer Index to determine the likely cause of anemia allows healthcare providers to

offer more specific dietary recommendations. Pregnant women diagnosed with IDA can receive targeted guidance on iron-rich foods and the use of iron supplements, while those with thalassemia trait can focus on balanced nutrition without additional iron intake. Such personalized counseling is crucial in managing anemia effectively and promoting optimal maternal nutrition throughout pregnancy.

7. Improved Diagnostic Accuracy When Used with Other Indices

When combined with other hematologic indices, such as red cell distribution width (RDW) and the Shine and Lal Index, the Mentzer Index can improve the diagnostic accuracy of differentiating between IDA and thalassemia. This combination approach can enhance the reliability of anemia screening, providing a more comprehensive picture and guiding effective management decisions. By using the Mentzer Index alongside other indices, healthcare providers can maximize the benefits of preliminary screening and reduce the need for more extensive testing, offering a balanced approach to managing anemia in pregnancy.

Limitations and Challenges

1. Limited Diagnostic Specificity

While the Mentzer Index is helpful for initial differentiation between iron deficiency anemia (IDA) and thalassemia trait, its specificity is limited. The index may not accurately distinguish between these types of anemia if a patient has concurrent conditions, such as both IDA and thalassemia, or other forms of microcytic anemia (e.g., anemia of chronic disease). This lack of specificity can lead to misdiagnosis or a delay in identifying the correct type of anemia, especially in complex cases where anemia arises from multiple causes.

2. Inaccuracies in Borderline Cases

The Mentzer Index uses a fixed threshold value (typically 13), but in borderline cases, results may be ambiguous or fall close to this cutoff. In such cases, the index may yield inconclusive results, necessitating further testing to confirm the diagnosis. Additionally, variations in individual physiology or laboratory testing methods can slightly influence MCV and RBC values, impacting the index's accuracy. This limitation underscores the need for complementary indices or additional testing in cases where the Mentzer Index result is inconclusive.

3. Dependence on Basic Hematologic Parameters

The accuracy of the Mentzer Index is directly dependent on the reliability of MCV and RBC count data. Variability in laboratory quality or errors in hematologic measurements can lead to incorrect index values, potentially affecting diagnosis and treatment decisions. In cases where high-quality laboratory infrastructure is unavailable or results are inconsistent, the reliability of the Mentzer Index as a screening tool is compromised, which can be a particular challenge in low-resource settings.

4. Insufficient for Comprehensive Anemia Diagnosis

The Mentzer Index does not account for other critical factors affecting anemia, such as inflammation, chronic disease, or vitamin deficiencies (e.g., folate or vitamin B12 deficiencies). As such, it is insufficient for a comprehensive diagnosis of anemia types beyond IDA and thalassemia trait. Pregnant women with complex health conditions or underlying chronic diseases may require additional testing to accurately identify and manage anemia, as reliance on the Mentzer Index alone may result in overlooked or misdiagnosed conditions.

5. Limited Utility in Severe Anemia Cases

In cases of severe anemia where MCV and RBC counts are significantly altered, the Mentzer Index may be less reliable, as both IDA and thalassemia trait can present with extreme microcytosis and low RBC counts in advanced stages. This

limitation reduces the tool's effectiveness in late-stage or untreated anemia, where overlapping symptoms and hematologic values make differentiation challenging. In such cases, further diagnostic testing, such as serum ferritin levels or hemoglobin electrophoresis, is often necessary.

6. Potential for Misinterpretation Without Clinical Context

The Mentzer Index is best used within a broader clinical context, as its interpretation relies on understanding the patient's full health history and any existing conditions. In pregnancy, where physiological changes affect blood parameters, interpreting the Mentzer Index without considering these changes can lead to inaccurate conclusions. For example, a slightly elevated RBC count due to normal pregnancy changes could skew the index's results, leading to misdiagnosis if used in isolation.

7. Dependency on Cutoff Values Without Adjustment for Individual Variability

The Mentzer Index uses a generalized cutoff of 13 to differentiate anemia types, but this value may not be universally applicable across different populations or genetic backgrounds. Factors such as age, ethnicity, geographic location, and overall health can influence MCV and RBC count, potentially affecting the accuracy of the cutoff threshold. Adjustments to the Mentzer Index may be needed to increase accuracy in diverse populations, yet standardized guidelines for such adjustments are currently limited, posing a challenge in ensuring accurate anemia diagnosis in pregnancy across varied demographics.

Alternative Diagnostic Indices

1. Red Cell Distribution Width (RDW) Index

The Red Cell Distribution Width (RDW) index is a measure of the variability in the size of red blood cells (RBCs), expressed as a percentage.[14] RDW is often elevated in iron deficiency anemia (IDA) due to the increased variability in cell size (anisocytosis), while it tends to be normal in thalassemia trait since most RBCs are similarly small. When used alongside mean corpuscular volume (MCV), RDW can help differentiate IDA from thalassemia. Higher RDW values suggest IDA, as it is characterized by a mix of small and normal-sized RBCs due to iron availability issues, while thalassemia trait usually shows low MCV and normal RDW.

2. Shine and Lal Index

The Shine and Lal Index is calculated by dividing the square of the MCV by the hemoglobin concentration.[15] A Shine and Lal Index value below 1530 generally indicates thalassemia trait, while a higher value suggests iron deficiency anemia. This index is particularly useful for distinguishing between microcytic hypochromic anemias and can add diagnostic value, especially in borderline cases where the Mentzer Index alone might be inconclusive.

3. Srivastava Index

The Srivastava Index is calculated by dividing the MCV by the hemoglobin level.[16] If the result is less than 3.8, it suggests thalassemia trait; if it's higher, IDA is more likely. The Srivastava Index provides a straightforward approach to anemia differentiation, though it's used less frequently compared to other indices. When combined with other markers like RDW and RBC count, it can enhance diagnostic clarity.

4. Red Cell Distribution Width Index (RDWI)

RDWI values above 220 are indicative of IDA, while values below 220 are suggestive of thalassemia trait. RDWI is particularly valuable in populations with high prevalence rates of both IDA and thalassemia, as it offers an alternative to the Mentzer Index and performs well in differentiating microcytic anemia types when used with RDW.

5. Green and King Index

The Green and King Index uses MCV, mean corpuscular hemoglobin (MCH), and RBC count.

If the index value is below 65, thalassemia is likely; if it's higher, IDA is more probable. The Green and King Index is known for its specificity and sensitivity, making it a reliable alternative for anemia diagnosis in pregnancy and other patient populations. This index, however, is more complex to calculate than the Mentzer Index, which can limit its practicality in primary care settings.[16]

6. England and Fraser Index

Negative values of this index are indicative of thalassemia, while positive values suggest IDA. The England and Fraser Index is more complex than the Mentzer Index but provides improved diagnostic differentiation in some cases, especially when used alongside other indices.[17]

7. Ricerca Index

The Ricerca Index, similar to other indices, helps differentiate microcytic anemias by using the RBC count and MCV.[18] Values below a certain threshold indicate thalassemia trait, while higher values suggest IDA. The Ricerca Index is particularly helpful when other tests or resources are limited and serves as an additional tool in settings where thalassemia and IDA overlap frequently.

Clinical Implications and Recommendations

1. Enhanced Screening Protocols

The incorporation of the Mentzer Index and alternative diagnostic indices into routine prenatal screening protocols for anemia is essential. Healthcare providers should ensure that these indices are calculated during initial blood tests to facilitate early detection of anemia types. Integrating these tools can help in promptly identifying pregnant women at risk of iron deficiency anemia (IDA) or thalassemia trait, allowing for timely interventions. Additionally, leveraging a combination of indices, such as RDW, Shine and Lal, and Srivastava Index, can enhance diagnostic accuracy, ultimately leading to improved maternal and fetal health outcomes.

2. Tailored Management Strategies

Following the differentiation of anemia types, tailored management strategies should be implemented based on the specific diagnosis. For patients identified with IDA, appropriate iron supplementation, dietary counseling, and monitoring for response to treatment should be prioritized. Conversely, for those diagnosed with thalassemia trait, it is crucial to avoid unnecessary iron supplementation and instead focus on regular monitoring and supportive care. Educating patients about their specific condition and management strategies is vital to fostering compliance and ensuring optimal health outcomes.

3. Regular Monitoring and Follow-Up

Continuous monitoring of hemoglobin levels, MCV, and RBC counts is necessary for pregnant women diagnosed with any form of anemia. Regular follow-up visits should be scheduled to assess treatment efficacy and adjust management plans as needed. This is particularly important for women with thalassemia trait, as they may experience fluctuating hemoglobin levels throughout pregnancy. Implementing a systematic approach for monitoring ensures that anemia does not progress to more severe forms, reducing the risk of complications such as preterm birth, low birth weight, and maternal fatigue.

4. Multidisciplinary Collaboration

Establishing a multidisciplinary approach to anemia management in pregnancy is critical. Collaboration between obstetricians, hematologists, nutritionists, and primary care providers can facilitate comprehensive care for pregnant women. Hematologists can provide expertise in complex anemia cases, while nutritionists can offer tailored dietary advice to ensure adequate nutrient intake. By fostering teamwork among healthcare professionals, the

overall management of anemia can be improved, ultimately benefiting maternal and fetal health.

5. Patient Education and Empowerment

Empowering patients through education about the significance of anemia and its potential impacts on pregnancy is vital. Healthcare providers should offer resources that explain the different types of anemia, the role of diagnostic indices, and the importance of adherence to treatment regimens. Encouraging patients to engage in discussions about their health, ask questions, and understand their treatment plans can enhance compliance and lead to better health outcomes. Providing culturally sensitive educational materials can also help address the diverse backgrounds and beliefs of pregnant women.

6. Research and Development of New Diagnostic Tools

Continued research into the development of new diagnostic tools and indices is essential to improve the accuracy and efficiency of anemia diagnosis in pregnancy. Innovative technologies, such as point-of-care testing and artificial intelligence algorithms, could offer rapid and precise identification of anemia types. Additionally, studies examining the population-specific applicability of existing indices can refine their use in diverse populations, ensuring that diagnostic tools are both effective and relevant.

7. Policy Implications for Healthcare Access

Policymakers should advocate for improved access to prenatal care and anemia screening in underserved populations, where anemia prevalence is often higher. Ensuring that healthcare facilities are equipped with the necessary resources and personnel to conduct routine screenings and follow-up care is crucial. Programs aimed at increasing awareness of anemia and providing education on nutrition and health during pregnancy should also be prioritized. By addressing the systemic barriers to healthcare access, maternal and fetal outcomes can be significantly improved, reducing the burden of anemia in pregnancy.[19]

Conclusion

The Mentzer Index, along with alternative diagnostic indices, plays a crucial role in the accurate differentiation of types of anemia during pregnancy, particularly between iron deficiency anemia and thalassemia trait. These indices offer valuable insights into the underlying causes of anemia, facilitating timely diagnosis and management. Given the significant implications of anemia on maternal and fetal health, the adoption of these tools in clinical practice is essential. While the Mentzer Index provides a straightforward method for assessing microcytic anemias, it is important to recognize its limitations and the challenges posed by overlapping clinical features. Thus, the integration of additional diagnostic indices, such as the Shine and Lal Index, RDW, and the Srivastava Index, enhances diagnostic accuracy and enables a more nuanced understanding of a patient's condition.

References

1. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. The American journal of clinical nutrition. 2016; 103(2):495-504.
2. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8.
3. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.

4. Petrakos G, Andriopoulos P, Tsironi M. Pregnancy in women with thalassemia: challenges and solutions. International journal of women's health. 2016:441-451.
5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 Apr;9(4):145-8.
6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. Journal of Public Health and Nutrition. 2023;6(1):138.
7. Arora S, Rana D, Kolte S, Dawson L, Dhawan I. Validation of new indices for differentiation between iron deficiency anemia and beta thalessemia trait, a study in pregnant females. International Journal of Scientific Reports. 2018; 4(2):26.
8. Tabassum S, Khakwani M, Fayyaz A, Taj N. Role of Mentzer index for differentiating iron deficiency anemia and beta thalassemia trait in pregnant women. Pakistan Journal of Medical Sciences. 2022;38(4Part-II):878.
9. Matos JF, Dusse LM, Stubbert RV, Ferreira MR, Coura-Vital W, Fernandes AP, de Faria JR, Borges KB, Carvalho MD. Comparison of discriminative indices for iron deficiency anemia and β thalassemia trait in a Brazilian population. Hematology. 2013 May 1;18(3):169-74.
10. Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, Aguilar Martinez P, Bou-Fakhredin R, Muckenthaler MU, Unal S, Porto G. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. Hemasphere. 2024; 8(7):e108.
11. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Apr 19;2(2):1-9.
12. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
13. Sahli CA, Bibi A, Ouali F, Fredj SH, Dakhlaoui B, Othmani R, Laouini N, Jouini L, Ouenniche F, Siala H, Touhami I. Red cell indices: differentiation between β-thalassemia trait and iron deficiency anemia and application to sickle-cell disease and sickle-cell thalassemia. Clinical Chemistry and Laboratory Medicine (CCLM). 2013; 51(11):2115-24.
14. Hoffmann JJ, Nabbe KC, van den Broek NM. Effect of age and gender on reference intervals of red blood cell distribution width (RDW) and mean red cell volume (MCV). Clinical Chemistry and Laboratory Medicine (CCLM). 2015; 53(12):2015-9.
15. Miftahussurur M, Husada D, Ningtyas WS. ASSOCIATION ASSOCIATION OF SHINE AND LAL INDEX β-THALASSEMIA TRAIT SCREENING RESULTS WITH ANAEMIA AND LOW BIRTH WEIGH. INTERNATIONAL JOURNAL OF NURSING AND MIDWIFERY SCIENCE (IJNMS). 2023; 7(3):290-296.
16. Shahid H, Saleem M, Naseer N, Tabussam S, Aziz A, Ullah S. Evaluation of Srivastava index to distinguishing Beta-Thalassemia Trait from Iron Deficiency. Pakistan Journal of Medical & Health Sciences. 2022;16(05):1225-.
17. Vehapoglu A, Ozgurhan G, Demir AD, Uzuner S, Nursoy MA, Turkmen S, Kacan A. Hematological indices for differential diagnosis of Beta thalassemia trait and iron deficiency anemia. Anemia. 2014; 2014(1):576738.
18. Urrechaga E. Discriminant value of% microcytic/% hypochromic ratio in the differential diagnosis of microcytic anemia. Clinical chemistry and laboratory medicine. 2008;46(12):1752-1758.

19. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18

Access this Article in Online	
	Website: www.ijcrcps.com
Quick Response Code	Subject: Hematology
DOI: 10.22192/ijcrcps.2024.11.10.003	

How to cite this article:
Emmanuel Ifeanyi Obeagu and Getrude Uzoma Obeagu. (2024). The Role of the Mentzer Index in Diagnosing Anemia During Pregnancy: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 11(10): 16-26.
DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.10.003

